Log In
BCIQ
Print this Print this
 

Envarsus, Envarsus XR, tacrolimus (formerly LCP-Tacro)

  Manage Alerts
Collapse Summary General Information
Company Veloxis Pharmaceuticals A/S
DescriptionOnce-daily tablet formulation of tacrolimus delivered using the MeltDose technology
Molecular Target FK506 binding protein 1A 12kDa (FKBP1A) (FKBP12)
Mechanism of ActionCalcineurin inhibitor
Therapeutic ModalityMacrocycle

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$47.5M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/08/2012

$47.5M

Undisclosed

Undisclosed

Get a free BioCentury trial today